Clinical trial of nimodipine combine with butylphthalide in the treatment of patients with mild to moderate vascular cognitive impairment
10.3760/cma.j.issn.1008-6706.2019.11.015
- VernacularTitle: 尼莫地平联合丁苯酞治疗轻中度血管性认知障碍的临床研究
- Author:
Gezhi ZHOU
1
;
Fan YANG
;
Minfeng TONG
Author Information
1. Department of Neurosurgery, Jinhua Municipal Central Hospital, Jinhua, Zhejiang 321000, China
- Publication Type:Journal Article
- Keywords:
Cognition disorders, vasculogenic;
Drug therapy, combination;
C-reaction protein;
Interleukins 6;
Tumor necrosis factorα
;
Comparative effectiveness research;
Nimodipine;
Butylphthalide
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(11):1343-1346
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy and safety of nimodipine combine with butylphthalide in the treatment of patients with mild to moderate vascular cognitive impairment(VCI).
Methods:From January 2012 to December 2016, 100 patients with mild to moderate VCI in Jinhua Municipal Central Hospital were randomly divided into control group(n=50) and treatment group(n=50) according to the random number table method.The control group received butylphthalide capsule, 200 mg po tid.The treatment group received nimodipine tablets, 40mg po tid, on the basis of the control group.The two groups of patients were treated for 24 weeks.Montreal cognitive assessment(MoCA), activities of daily living(ADL), serum hs-CRP, IL-6, TNF-α, clinical efficacy and adverse drug reactions were compared after treatment.
Results:After treatment, the scores of MoCA and ADL in the treatment group were (24.32±2.87)points, (59.22±6.17)points, respectively, which were significantly higher than those in the control group[(22.76±2.67)points, (55.63±6.3)points, t=2.814, 2.870, all P<0.05]. The effective rates in the treatment group and control group were 74.00%(37/50), 52.00%(26/50), respectively, and there was statistically significant difference between the two groups(χ2=5.191, P<0.05). After treatment, the levels of hs-CRP[(189.51±23.27)mg/L vs.(211.51±25.51)mg/L], IL-6[(76.42±9.86)ng/L vs.(95.85±10.23)ng/L], TNF-α[(0.24±0.08)ng/L vs.(0.32±0.10)ng/L] between the treatment group and the control group had statistically significant differences(t=4.505, 9.670, 4.417, all P<0.05). The adverse drug reactions were nausea and vomiting in 3 cases in the control group(6.00%), nausea and vomiting in 3 cases and hypotension in 1 case in the treatment group(8.00%), and there was no statistically significant difference between the two groups(P>0.05).
Conclusion:Nimodipine combined with butylphthalide in the treatment of mild to moderate VCI is effective and has high safety.
